No Data
No Data
10-Q: Quarterly report
Express News | ProMIS Neurosciences Inc: On Track to Report Top-Line Data From Phase 1a Portion of Pmn310 Study in Mid-2024
ProMIS Neurosciences Inc Files For Shelf Of Up To 22.1M Common Shares By Selling Stockholders
ProMIS Neurosciences Inc Files For Shelf Of Up To 22.1M Common Shares By Selling Stockholders
ProMIS Neurosciences Inc. PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared To Other Amyloid-Beta-Directed Antibodies In Poster Presentation At AD/PD 2023
ProMIS Neurosciences Inc. (TSX:PMN) (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative dis
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) ("ProMIS" or the "Company"), a biotechnology company focused on th
ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) ("ProMIS" or the "Company"), a biotechnology company focused on
No Data